

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

NCT06393712

Status	RECRUITING
Phase	Phase 2
Sponsor	Alnylam Pharmaceuticals
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (4)

- Is 50 years or older
- Has probable CAA per the Boston Criteria Version 2.0
- Is 30 years or older
- Has known E693Q amyloid precursor protein (APP) gene mutation for Dutch-type CAA

Exclusion (6)

- Moderate or severe stage Alzheimer's disease (AD) or significant cognitive impairment (CI)
- Has a history of previous clinical intracerebral hemorrhage (ICH) with onset less than 90 days prior to anticipated randomization in the study
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) $>3 \times$ upper limit of normal (ULN) at Screening
- Has estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² at Screening
- Has recently received an investigational agent
- ... and 1 more (see full listing online)

Locations (57 total)

Clinical Trial Site, Los Angeles, California, United States
Clinical Trial Site, Orange, California, United States
Clinical Trial Site, Palo Alto, California, United States
... and 54 more locations